Financials data is unavailable for this security.
View more
Year on year Ultragenyx Pharmaceutical Inc grew revenues 19.52% from 363.33m to 434.25m while net income improved from a loss of 707.42m to a smaller loss of 606.64m.
Gross margin | 87.15% |
---|---|
Net profit margin | -121.57% |
Operating margin | -114.04% |
Return on assets | -39.94% |
---|---|
Return on equity | -208.43% |
Return on investment | -48.51% |
More ▼
Cash flow in USDView more
In 2023, Ultragenyx Pharmaceutical Inc increased its cash reserves by 59.45%, or 81.80m. Cash Flow from Financing totalled 388.14m or 89.38% of revenues. In addition the company used 474.81m for operations while cash from investing totalled 168.00m.
Cash flow per share | -6.82 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.69 |
---|---|
Tangible book value per share | 2.41 |
More ▼
Balance sheet in USDView more
Current ratio | 3.54 |
---|---|
Quick ratio | 3.39 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼